Berenberg Cuts Grifols’ Potential by 23%, but Continues to Bet on its Shares

Ups and downs for Grifols. The analysis firm Berenberg has cut the target price of the shares of the Spanish blood products company by 23%, from 25.8 euros to 19.8 euros.

Berenberg still remains optimistic regarding Grifols’ upward potential

The financial institution Berenberg was already optimistic in February after the publication of a report by the bearish fund Gotham City Research that accused Grifols of artificially reducing its leverage, but has changed its criteria after the Catalan company reported a higher than expected net debt .

All in all, Berenberg remains optimistic regarding Grifols’ upward potential, which he places at 134% compared to yesterday’s close. So far this year, the value of the blood products company’s shares has fallen 44%, weighed down by Gotham’s offensive and the persistence of other bearish funds that have bet against the company.

Last week, Grifols announced the signing of a private placement of €1 billion in 7.5% senior secured bonds, maturing in April 2030 , subject to the usual closing conditions for this type of transaction. According to company sources, the funds obtained from this transaction will be used to amortize unsecured bonds maturing in 2025.

Grifols will provide real guarantees granted and the respective guarantors to the buyers of the senior bonds

The Catalan company detailed that the terms and guarantees of these bonds are “significantly consistent” with the existing documentation on Grifols’ secured debt, including the real guarantees granted and the respective guarantors. He also stated that this transaction represents an “important financial milestone,” underlining “the confidence of the financial markets in the solidity of Grifols’ business and operational resilience.”

The notes will not be registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an equivalent exemption from registration requirements.

Grifols has had Osborne Clarke and Proskauer Rose LLP as legal advisors for this operation, while Deutsche Bank has been the company’s placement agent.

Europacific Growth Fund Lends Over 100 Million Euros in Grifols Shares

Europacific Growth Fund, legal owner of Grifols shares, has lent more than 100 million euros in shares of the blood products firm, which amounts to a total amount of 13.1 million shares, according to the documentation contained in the National Securities Market Commission (Cnmv).

Specifically, Europacific Growth Fund, which has reduced its participation in Grifols’ capital from 3.4% to 3.2%, distributes its position in the Spanish firm between 0.14% of voting rights attributed to the shares and 3.07% through financial instruments, which were notified to the supervisor last Friday, March 15th.

The latest registered notification also shows that the percentage of voting rights attributed to the shares has decreased from 2.25% (9.6 million shares) to 0.14% (631,807 shares), reflecting that Europacific Growth Fund has disposed of a package of 8,972,419 Grifols shares, valued at more than 69 million euros based on current market prices.

__

(Featured image by 6689062 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us